www.va.se
finansavisen.no
PCI Biotech OSL:PCIB is a biopharmaceutical company focusing on development and commercialisation of novel therapeutic solutions for improved treatment of cancer patients through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that can be used to unlock the...
PCI Biotech Holding OSL:PCIB stock has been consolidating in a trading range below last years 30 NOK shareprice rights issue of NOK 360 million.
Positive market reaction to the latest quarterly report from the company, along with good coverage in magasines:
www.tu.no (norwegian language)
nordiclifescience.org (page 91-94)
At the moment, the stock is...
